论文部分内容阅读
目的探讨Grave病患者采用131I治疗前后血清中白细胞介素-2(IL-2)及白细胞介素-12 p40(IL-12p40)含量的改变及细胞因子在该疾病中的作用与意义。方法采用酶联免疫吸附试验双抗夹心法、放射免疫法,对2009年10月-2011年12月收治的28例Grave病患者(治疗组)经131I治疗前后血清中IL-2和IL-12p40含量进行自身对比及与健康志愿者(对照组)对比;同时对治疗组患者治疗前、后的血清游离三碘甲腺原氨酸(FT3)、血清游离甲状腺素(FT4)、促甲状腺激素(TSH)水平与对照组进行对比。结果治疗后患者血清中IL-2和IL-12p40的水平为(19.54±11.17)、(615.88±349.32)ng/mL,明显高于治疗前(P<0.05),且与对照组比较差异无统计学意义(P>0.05);患者治疗前后血清中IL-2和IL-12p40水平与FT3、FT4水平有显著相关性。结论血清IL-2和IL-12p40可能共同参与Grave病的发病过程,并且这两种因子的水平与FT3、FT4水平呈负相关性。
Objective To investigate the changes of serum interleukin-2 (IL-2) and interleukin-12 (p40) (IL-12p40) levels and the significance of cytokines in patients with Grave’s disease before and after treatment with 131I. Methods Serum levels of IL-2 and IL-12p40 in patients with Grave disease (treatment group) after 131I treatment from October 2009 to December 2011 were detected by enzyme-linked immunosorbent assay (ELISA), double antibody sandwich method and radioimmunoassay (FT3), serum free thyroxine (FT4), thyroid stimulating hormone (FT4) and thyroid stimulating hormone TSH) levels compared with the control group. Results The levels of IL-2 and IL-12p40 in serum of patients after treatment were (19.54 ± 11.17) and (615.88 ± 349.32) ng / mL, respectively, which were significantly higher than those before treatment (P <0.05) Significance (P> 0.05). Serum levels of IL-2 and IL-12p40 in patients before and after treatment were significantly correlated with FT3 and FT4 levels. Conclusions Serum IL-2 and IL-12p40 may participate in the pathogenesis of Grave’s disease, and the levels of these two factors are negatively correlated with FT3 and FT4 levels.